Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for SORAFENIB TOSYLATE
- Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
- Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
- Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor
- Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
- Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
- Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies
- Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
- Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
- Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
- Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
- Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
- Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
- Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
- Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma
- Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
- Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
- Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
- Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
- Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
- Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma
- Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
- Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia
- Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia
- Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
- Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
- Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
- Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors
- Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
- Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
- Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
- Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
- Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases
- Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
- Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder
- Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery
- Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
- Sorafenib. ICORG 06-41, V4
- Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)
- Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer
- Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
- Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis
- Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer
- Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
- Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
- Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
- Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
- Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
- Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)
- Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery
- Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer
- Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
- Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
- Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery
- Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
- Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery
- Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery
- External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
- Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab
- Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
- Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
- Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
- Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer
- Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
- Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma
- Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma
- Sorafenib in Treating Patients With Advanced Malignant Solid Tumors
- Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy
- Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis
- Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
- Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
- Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
- Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
- Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
- Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
- Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
- Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma
- PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
- Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
- Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
- Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors
- Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg
- Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
- Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
- Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
- Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer
- Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
- Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
- Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer
- Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
- Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
- Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies
- Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
- Sorafenib in Treating Patients With Advanced Solid Tumors
- Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer
- Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
- Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
- Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
- Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
- Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
- Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
- Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
- Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye
- Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
- Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
- Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
- Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain
- Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
- Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
- Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
- Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors
- Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
- Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer
- S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma
- Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
- Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia
- Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
- Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer
- Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
- Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
- Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
- Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
- Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer
- Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors
- Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
- Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
- Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
- 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
- Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
- Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
- Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function
- Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
- Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
- Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
- Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
- Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
- Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
- Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
- Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
- S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
- Sorafenib in Treating Patients With Metastatic Breast Cancer
- Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer
- Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
- Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
- Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
- Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
- Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer
Clinical trials list
click for details